Adaptive Biotechnologies (ADPT) Competitors $13.31 +0.34 (+2.62%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$13.30 -0.01 (-0.04%) As of 08/28/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADPT vs. TWST, TXG, VCYT, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, and AXSMShould you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Twist Bioscience (TWST), 10x Genomics (TXG), Veracyte (VCYT), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), and Axsome Therapeutics (AXSM). These companies are all part of the "medical" sector. Adaptive Biotechnologies vs. Its Competitors Twist Bioscience 10x Genomics Veracyte Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Axsome Therapeutics Adaptive Biotechnologies (NASDAQ:ADPT) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Do institutionals and insiders hold more shares of ADPT or TWST? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 3.0% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend ADPT or TWST? Adaptive Biotechnologies currently has a consensus price target of $12.38, indicating a potential downside of 7.02%. Twist Bioscience has a consensus price target of $49.40, indicating a potential upside of 85.78%. Given Twist Bioscience's higher probable upside, analysts plainly believe Twist Bioscience is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the media favor ADPT or TWST? In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Twist Bioscience. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 8 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.12 beat Adaptive Biotechnologies' score of 0.84 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ADPT or TWST? Adaptive Biotechnologies has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M11.32-$159.49M-$0.82-16.23Twist Bioscience$362.27M4.43-$208.73M-$1.45-18.34 Which has more risk & volatility, ADPT or TWST? Adaptive Biotechnologies has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Is ADPT or TWST more profitable? Twist Bioscience has a net margin of -23.51% compared to Adaptive Biotechnologies' net margin of -59.07%. Twist Bioscience's return on equity of -29.03% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% Twist Bioscience -23.51%-29.03%-21.77% SummaryAdaptive Biotechnologies and Twist Bioscience tied by winning 8 of the 16 factors compared between the two stocks. Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADPT vs. The Competition Export to ExcelMetricAdaptive BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.97B$3.10B$5.78B$9.79BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-16.2321.0831.2626.59Price / Sales11.32361.89431.16158.34Price / CashN/A44.6737.7359.36Price / Book11.288.0910.046.68Net Income-$159.49M-$54.08M$3.27B$265.59M7 Day Performance2.38%-0.41%1.34%0.66%1 Month Performance28.10%6.23%6.13%2.64%1 Year Performance185.01%10.45%41.90%22.36% Adaptive Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADPTAdaptive Biotechnologies2.5408 of 5 stars$13.31+2.6%$12.38-7.0%+195.1%$1.97B$178.96M-16.23790TWSTTwist Bioscience4.0393 of 5 stars$28.02-0.4%$49.40+76.3%-39.8%$1.70B$312.97M-19.32990Positive NewsTXG10x Genomics3.7389 of 5 stars$13.46+0.7%$13.54+0.6%-35.9%$1.66B$610.78M-19.231,240Insider TradeVCYTVeracyte2.3931 of 5 stars$30.07-0.5%$40.90+36.0%-5.3%$2.38B$445.76M91.12790Positive NewsGRFSGrifols3.6274 of 5 stars$10.58-1.3%$10.30-2.6%+9.7%$7.37B$7.45B9.0423,822Positive NewsLEGNLegend Biotech3.8905 of 5 stars$37.45-0.1%$72.38+93.3%-39.3%$6.89B$627.24M-42.562,609Positive NewsAnalyst ForecastRVMDRevolution Medicines4.3339 of 5 stars$36.45+0.4%$69.54+90.8%-10.1%$6.79B$11.58M-8.10250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.6652 of 5 stars$98.09+0.5%$101.57+3.5%+124.7%$6.48B$130.13M-32.59140Positive NewsInsider TradeRNAAvidity Biosciences3.1424 of 5 stars$44.48-4.3%$67.00+50.6%+11.3%$5.98B$10.90M-12.49190Positive NewsNUVLNuvalent3.4335 of 5 stars$75.01-1.4%$119.60+59.4%-10.2%$5.48BN/A-15.3140News CoveragePositive NewsAXSMAxsome Therapeutics4.7804 of 5 stars$111.13+1.8%$178.00+60.2%+37.7%$5.45B$385.69M-21.92380News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies Twist Bioscience Competitors 10x Genomics Competitors Veracyte Competitors Grifols Competitors Legend Biotech Competitors Revolution Medicines Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Nuvalent Competitors Axsome Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADPT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access